Trichomegaly of the eyelashes following treatment with cetuximab

Vaccaro, Mario; Pollicino, A; Barbuzza, Olga; Guarneri, Biagio

doi:10.1111/j.1365-2230.2008.02842.x

Cited by 26 publications

(16 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[8,12,15,16,19] Mucocutaneous reactions to EGFR inhibitors are summarized in table I. [1][2][3][4][5][6]9,11,14,15,17,19,20,[22][23][24][25][26][27][28][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44] These include not only increased (hypertrichosis) and decreased (alopecia) Acral fissures Fissures occur on the hands and feet, fingers (tips and interphalangeal joints), and toes. [8,15,26] Indeed, the papulopustular eruption has been associated with favorable tumor response, lengthening of time to progression, and improved overall survival.…”

Section: Discussionmentioning

confidence: 99%

“…Acquired eyelash trichomegaly has been described in individuals in whom the elongation of their eyelashes is associated with either systemic disease or infection, topical or systemic drug treatment, or an underlying cancer. [1,4,5,36,38] Trichomegaly of the eyelashes has also been reported in patients treated with other monoclonal antibodies to EGFR such as panitumumab. [1][2][3][4][5]14,24,[36][37][38][39][40][41] The drug is usually delivered at an initial dose of 400 mg m 2 followed by weekly infusions of 250 mg m 2 ; [1,3,4] the patients may also be receiving radiotherapy [3] or irinotecan.…”

Section: Miscellaneousmentioning

confidence: 95%

“…Congenital eyelash trichomegaly has been observed in patients with Oliver-McFarlane syndrome and type I oculocutaneous albinism. [1][2][3][4][5]14,24,[36][37][38][39][40][41] The drug is usually delivered at an initial dose of 400 mg m 2 followed by weekly infusions of 250 mg m 2 ; [1,3,4] the patients may also be receiving radiotherapy [3] or irinotecan. [33] Similar to our patient, eyelash trichomegaly has been described in other individuals receiving cetuximab.…”

Section: Miscellaneousmentioning

confidence: 99%

See 2 more Smart Citations

Cetuximab-Associated Elongation of the Eyelashes

Cohen

Escudier

Kurzrock

2011

American Journal of Clinical Dermatology

View full text Add to dashboard Cite

Eyelash trichomegaly is an uncommon drug-associated sequelae experienced during treatment with epidermal growth factor receptor (EGFR) inhibitors. Elongation of the eyelashes induced by these agents has predominantly been observed in oncology patients with either colorectal or lung cancer. It is most frequently associated with cetuximab and erlotinib; however, it has also been described in individuals treated with gefitinib or panitumumab. We describe cetuximab-associated eyelash trichomegaly in a woman with metastatic rectal carcinoma. We review the clinical presentation, adverse effects, and management of EGFR inhibitor-related eyelash trichomegaly. The long eyelashes are not a drug-limiting adverse effect and some patients consider the change to be cosmetically enhancing. Trimming the lashes with scissors can usually ameliorate local symptoms. The eyelashes often return to their original length at variable time periods after EGFR inhibitor therapy is discontinued.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Miscellaneousmentioning

confidence: 95%

Section: Miscellaneousmentioning

confidence: 99%

See 1 more Smart Citation

Cetuximab-Associated Elongation of the Eyelashes

Cohen

Escudier

Kurzrock

2011

American Journal of Clinical Dermatology

View full text Add to dashboard Cite

show abstract

“…Dermatologic side effects of cetuximab include acneiform eruptions, seborrhoeic-like dermatitis, trichomegaly, eczema, xerosis, desquamation, paronychia, hair changes, telangiectasia and hyperpigmentation Suh et al, 2006;Vaccaro, 2008). Acneiform skin eruption is the most common adverse event of cetuximab therapy with an incidence of about 80 % (Gutzmer et al, 2005;.…”

Section: Case Reportmentioning

confidence: 99%

“…It is also found in many human cancers including those of the head and neck, colon and rectum. EGFR leads to tumour growth, increased resistance to chemotherapy or radiotherapy, and metastasis formation (Vaccaro, 2008).…”

Section: Case Reportmentioning

confidence: 99%

Acneiform Skin Lesions Associated With Cetuximab Therapy: Report of Two Cases

Yılmaz¹,

ÖZDEN²,

Aydın³

et al. 2010

jecm

View full text Add to dashboard Cite

Cetuximab, is an IgG1 chimeric monoclonal antibody type of epidermal growth factor receptor (EGFR). It is most commonly prescribed for metastatic colorectal cancer, administered alone or in combination with irinotecan-based chemotherapy regimens (Lee et al., 2008;Segaert and Cutsem 2005;Scope et al., 2009). Acneiform eruption is the most common adverse effect with 80% of incidence (Segaert and Cutsem 2005;Lee et al., 2008). We report two cases of severe acneiform eruption induced by cetuximab with metastatic colorectal cancer.

show abstract

Current awareness: Pharmacoepidemiology and drug safety

2009

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 23 sections: 1 Reviews; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Antidiabetic Agents; 21 Contrast Agents; 22 Bone Conservation Agents; 23 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Trichomegaly of the eyelashes following treatment with cetuximab

Cited by 26 publications

References 5 publications

Cetuximab-Associated Elongation of the Eyelashes

Cetuximab-Associated Elongation of the Eyelashes

Acneiform Skin Lesions Associated With Cetuximab Therapy: Report of Two Cases

Current awareness: Pharmacoepidemiology and drug safety

Contact Info

Product

Resources

About